Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

Amer Zeidan, MBBS, MHS
Published: Saturday, May 02, 2015



Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Zeidan says this analysis looked at nearly 32,000 patients aged 69-99 at diagnosis who underwent surgery. The analysis compared patients who then underwent radiotherapy to those who did not. The study showed that patients who underwent radiotherapy had a slight risk of developing therapy-related MDS and acute myeloid leukemia, Zeidan says.

Therefore, physicians need to have discussions with their patients before continuing to radiotherapy.

<<< View more from the 2015 MDS Symposium



Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Zeidan says this analysis looked at nearly 32,000 patients aged 69-99 at diagnosis who underwent surgery. The analysis compared patients who then underwent radiotherapy to those who did not. The study showed that patients who underwent radiotherapy had a slight risk of developing therapy-related MDS and acute myeloid leukemia, Zeidan says.

Therefore, physicians need to have discussions with their patients before continuing to radiotherapy.

<<< View more from the 2015 MDS Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x